Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477581 | 0.81 | — | — | |
| SCHEMBL9963226 | 0.81 | NOS1 (0.32) | NOS1HRH1KCNH2 | |
| SCHEMBL20374741 | 0.77 | NOS1 (0.34) | NOS1HRH1KCNH2 | |
| SCHEMBL18994385 | 0.77 | NOS1 (0.31) | NOS1HRH1KCNH2 | |
| SCHEMBL28118277 | 0.76 | — | — | |
| SCHEMBL1696877 | 0.76 | — | — | |
| SCHEMBL2575521 | 0.75 | — | — | |
| SCHEMBL5713342 | 0.75 | NOS1 (0.34) | NOS1HRH1KCNH2 | |
| SCHEMBL174399 | 0.75 | — | — | |
| Bromide SCHEMBL27878723 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119246-A1 | 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-02 | — | — | US | disclosed |
| EP-1465871-A1 | PYRAZOLE DERIVATIVES FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | Bayer Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057673-A1 | 1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119246-A1 | 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction | HTR2C, GPR119, HTR2B | NOS1 763/4885HRH1 728/4885KCNH2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.